Table 1.
Baseline characteristics for biologic disease-modifying antirheumatic drug-naïve (COAST-V study) and tumor necrosis factor inhibitor inhibitor-experienced (COAST-W study) patients
| Baseline characteristics | Patient groups | |
|---|---|---|
| bDMARD-naïve (COAST-V study) (N = 341) | TNFi-experienced (COAST-W study) (N = 316) | |
| Age, years | 41.7 (11.7)b | 46.1 (12.4) |
| Male, n (%) | 276 (81.2)b | 253 (80.1) |
| Weight, kg | 78.1 (15.8)b | 83.2 (18.7) |
| Duration of r-axSpA symptoms, years | 16.0 (10.3)b | 18.4 (11.1) |
| Time since r-axSpA diagnosis, years | 7.7 (8.4)b | 11.6 (9.1) |
| C-reactive protein level, mg/L | 13.5 (17.1)b | 17.8 (26.6) |
| Therapy, n (%) | ||
| Current cDMARD use (including MTX) | 125 (36.8)b | 86 (27.2) |
| Current MTX use | 29 (8.5)b | 41 (13.0) |
| Current SSZ use | 97 (28.5)b | 46 (14.6) |
| IR to 1 TNFi | – | 205 (65.1)e |
| IR to 2 TNFi | – | 78 (24.8)e |
| Intolerance to TNFi | – | 32 (10.2)e |
| ASDAS | 3.8 (0.8)b | 4.1 (0.8) |
| Disease activity and pain | ||
| Patient global (disease activity) NRS | 7.0 (1.6)b | 7.9 (1.7) |
| Spinal pain NRS | 7.2 (1.5)b | 7.9 (1.5) |
| Spinal pain at night NRS | 7.0 (1.6)b | 7.7 (1.7) |
| Inflammation (BASDAI questions 5 and 6) | 6.7 (1.7)b | 7.3 (1.7) |
| Fatigue (fatigue NRS) | 6.8 (1.7)b | 7.3 (1.8) |
| Sleep (JSEQ) | 8.2 (5.2)b | 10.4 (5.6) |
| Reported part-time or full-time paid work, n (%) | 252 ( 74.1)b | 182 (57.6) |
| Work productivity (WPAI-SpA) | ||
| Absenteeisma | 10.9 (23.5)c | 18.1 (27.2)f |
| Presenteeisma | 56.8 (21.0)d | 60.7 ( 20.7)g |
| Overall work impairment scorea | 58.7 (22.0)d | 64.4 (21.5)g |
| Activity impairment | 60.3 (19.8)b | 70.7 (19.3) |
Data are presented as the mean with the standard deviation (SD) in parentheses, unless otherwise stated
ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, cDMARD conventional disease-modifying antirheumatic drug, IR inadequate responder, JSEQ Jenkins Sleep Evaluation Questionnaire, MTX methotrexate, N number of patients in the analysis category, NRS numeric rating score, r-axSpA radiographic axial spondyloarthritis, SSZ sulfasalazine, TNFi tumor necrosis factor inhibitor, WPAI-SpA Work Productivity and Activity Impairment Questionnaire for Ankylosing Spondylitis
aAbsenteeism, presenteeism, and overall work impairment were measured in patients reporting part- or full-time work
bN = 340
cN = 245
dN = 234
eN = 315
fN = 167
gN = 157